keyword
MENU ▼
Read by QxMD icon Read
search

rituximab hepatitis b reactivation

keyword
https://www.readbyqxmd.com/read/30210131/hepatitis-b-virus-reactivation-in-a-patient-with-nonalcoholic-steatohepatitis-41-months-after-rituximab-containing-chemotherapy-a-case-report
#1
Manabu Hayashi, Kazumichi Abe, Masashi Fujita, Ken Okai, Atsushi Takahashi, Hiromasa Ohira
Hepatitis B virus (HBV) reactivation occasionally occurs long after immunosuppressive therapy. The characteristics of late HBV reactivation remain unclear. We herein present a case of HBV reactivation in a patient with nonalcoholic steatohepatitis (NASH) more than 3 years after rituximab-containing chemotherapy for diffuse large B-cell lymphoma. Increased transaminase levels, which were induced by NASH, were observed after chemotherapy and were alleviated with statin treatment. HBV reactivation was identified incidentally...
September 12, 2018: Internal Medicine
https://www.readbyqxmd.com/read/30147140/detection-of-the-incidence-of-hbv-hcv-infection-and-febrile-neutropenia-associated-with-chop-with-or-without-rituximab-in-diffuse-large-b-cell-lymphoma-treated-patients
#2
Kashif Ali, Ali Akbar Sial, Mirza Tasawer Baig, Nida Baig, Saqib Hussain Ansari, Tahir Sultan Shamsi
Background: Reactivation of hepatitis B virus (HBV) and hepatitis C virus (HCV) and febrile neutropenia (FN) are common in diffuse large B-cell lymphoma (DLBCL) patients undergoing cyclophosphamide, hydroxyrubicin, Oncovin, and prednisolone (CHOP) or cyclophosphamide, hydroxyrubicin, Oncovin, prednisolone - rituximab containing (R-CHOP) chemotherapy. This ultimately leads to delaying the therapy, increasing hospital stay, and raising the pharmacoeconomic burden on patients. Aim and Objective: The aim of this study was to determine the incidence of HBV and HCV infection and febrile neutropenia in DLBCL patients treated with R-CHOP and CHOP...
June 2018: Hospital Pharmacy
https://www.readbyqxmd.com/read/30058572/three-year-follow-up-on-the-safety-and-effectiveness-of-rituximab-plus-chemotherapy-as-first-line-treatment-of-diffuse-large-b-cell-lymphoma-and-follicular-lymphoma-in-real-world-clinical-settings-in-china-a-prospective-multicenter-noninterventional-study
#3
Jian-Qiu Wu, Yong-Ping Song, Li-Ping Su, Ming-Zhi Zhang, Wei Li, Yu Hu, Xiao-Hong Zhang, Yu-Huan Gao, Zuo-Xing Niu, Ru Feng, Wei Wang, Jie-Wen Peng, Xiao-Lin Li, Xue-Nong Ouyang, Chang-Ping Wu, Wei-Jing Zhang, Yun Zeng, Zhen Xiao, Ying-Min Liang, Yong-Zhi Zhuang, Ji-Shi Wang, Zi-Min Sun, Hai Bai, Tong-Jian Cui, Ji-Feng Feng
Background: Prospective real-life data on the safety and effectiveness of rituximab in Chinese patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) are limited. This real-world study aimed to evaluate long-term safety and effectiveness outcomes of rituximab plus chemotherapy (R-chemo) as first-line treatment in Chinese patients with DLBCL or FL. Hepatitis B virus (HBV) reactivation management was also investigated. Methods: A prospective, multicenter, single-arm, noninterventional study of previously untreated CD20-positive DLBCL or FL patients receiving first-line R-chemo treatment at 24 centers in China was conducted between January 17, 2011 and October 31, 2016...
August 5, 2018: Chinese Medical Journal
https://www.readbyqxmd.com/read/29991894/hepatitis-b-virus-reactivation-in-hbsag-negative-anti-hbc-positive-patients-receiving-immunosuppressive-therapy-a-systematic-review
#4
Evangelos Cholongitas, Anna-Bettina Haidich, Fani Apostolidou-Kiouti, Parthenis Chalevas, George V Papatheodoridis
Background: The optimal management of HBsAg-negative, anti-HBc-positive patients who receive immunosuppression remains unclarified. We systematically reviewed the available data on potential predictors of the risk of hepatitis B virus (HBV) reactivation in such patients. Methods: A literature search identified 55 studies with 3640 HBsAg-negative, anti-HBc-positive patients who received immunosuppressive regimens. Results: HBV reactivation was reported in 236 (6...
July 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29977329/negative-effect-of-hepatitis-in-overall-and-progression-free-survival-among-patients-with-diffuse-large-b-cell-lymphoma
#5
Mubarak M Al-Mansour, Saif A Alghamdi, Musab A Alsubaie, Abdullah A Alesa, Muhammad A Khan
Background: Hepatitis B virus (HBV) is one of the most prevalent and serious infections worldwide. HBV reactivation is a serious complication for lymphoma patients who are being treated with rituximab-containing regimen. Since the impact of HBV has not been fully evaluated on the prognosis of diffuse large B cell lymphoma (DLBCL), this study examined the effect of the hepatitis infection on the progression-free survival (PFS) and overall survival (OS) in patients with DLBCL who received rituximab-containing chemotherapy...
2018: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/29940039/correction-randomized-prospective-study-evaluating-tenofovir-disoproxil-fumarate-prophylaxis-against-hepatitis-b-virus-reactivation-in-anti-hbc-positive-patients-with-rituximab-based-regimens-to-treat-hematologic-malignancies-the-preblin-study
#6
María Buti, María L Manzano, Rosa M Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M Zozaya, Miguel A Simón, Luis E Morano, José L Calleja, María Yébenes, Rafael Esteban
[This corrects the article DOI: 10.1371/journal.pone.0184550.].
2018: PloS One
https://www.readbyqxmd.com/read/29925294/a-response-to-the-letter-to-the-editor-on-management-of-hepatitis-b-reactivation-in-lymphoma-patients-on-rituximab-with-past-hepatitis-b-exposure-an-observational-study
#7
Denise Yeo, Ihtimam Hossain, Soon Thye Lim, Mohamad Farid, Miriam Tao, Richard Quek, Tiffany Tang, Alexandre Chan
No abstract text is available yet for this article.
September 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29845351/antiviral-prophylaxis-during-chemotherapy-or-immunosuppressive-drug-therapy-to-prevent-hbv-reactivation-in-patients-with-resolved-hbv-infection-a-systematic-review-and-meta-analysis
#8
REVIEW
Yi-Chia Su, Pei-Chin Lin, Hsien-Chung Yu, Chih-Chien Wu
BACKGROUND: Until recently, the role of antiviral prophylaxis in preventing hepatitis B virus (HBV) reactivation during immunosuppressive therapy or chemotherapy in patients with resolved HBV infection was unclear. The aim of the study reported here was to compare the efficacy of antiviral prophylaxis versus that of non-prophylaxis in resolved HBV-infected patients undergoing chemotherapy or immunosuppressive therapy. METHODS: PubMed, the Cochrane library, and the ClinicalTrials...
September 2018: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29725560/fatal-fulminant-hepatitis-from-rituximab-induced-hepatitis-b-reactivation-in-a-patient-with-follicular-lymphoma-a-case-report-and-a-brief-review-of-literature
#9
Zarak H Khan, Kamran Ilyas, Haider Ghazanfar, Hamza H Khan, Qulsoom Hussain, Sahla Hammad, Ahmed Munir, Rizwan Asim
The objective of our study was to recognize hepatitis B reactivation as a complication of rituximab chemotherapy and to realize the importance of screening for prior Hepatitis B virus (HBV) exposure in all patients with hematologic malignancies who will receive rituximab as part of their therapy. Rituximab is a monoclonal antibody targeting CD 20 receptors on the membrane of B cells. In this case report, we described a 79-year-old man who presented to our department with nausea, fatigue, and jaundice. Two months ago, he had received the last dose of the chemotherapy regimen containing rituximab for follicular B cell lymphoma...
March 2, 2018: Curēus
https://www.readbyqxmd.com/read/29649073/short-article-safety-of-targeted-prophylaxis-strategy-in-patients-with-resolved-hepatitis-b-virus-infection-receiving-rituximab-for-immune-mediated-diseases
#10
Michele Spinicci, Giacomo Emmi, Laura Dies, Alessandro Barilaro, Gianfranco Vitiello, Jessica Mencarini, Annalisa Cavallo, Alessandro Bartoloni, Filippo Bartalesi
OBJECTIVES: Rituximab (RTX) is a monoclonal antibody that is widely used in hematologic malignancies and immune-mediated diseases (IMID) and has been associated with the risk of hepatitis B virus reactivation (HBVr). Thus, antiviral prophylaxis is recommended before RTX treatment in all patients with chronic hepatitis B virus (HBV) infection and those with resolved infection affected by onco-hematological conditions. By contrast, the correct management of HBsAg-negative/HbcAb-positive patients candidates for RTX-containing regimens for IMID is still debated, owing to few data currently available in this setting...
July 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29621049/hepatitis-b-virus-reactivation-in-patients-with-resolved-hepatitis-b-virus-infection-receiving-chemotherapy-or-immunosuppressive-therapy
#11
Yi-Chia Su, Pei-Chin Lin, Hsien-Chung Yu, Chih-Chien Wu
BACKGROUND: The role of antiviral prophylaxis before chemotherapy or immunosuppressive therapy to prevent hepatitis B virus (HBV) reactivation in patients with resolved HBV infection [hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (anti-HBc) positive] is unclear. This study aimed to evaluate the efficacy of prophylactic antiviral therapy and outcomes of HBsAg-negative, anti-HBc-positive patients who received chemotherapy or immunosuppressive therapy. PATIENTS AND METHODS: We retrospectively evaluated the medical records of HBsAg-negative, anti-HBc-positive patients who underwent chemotherapy or immunosuppressive therapy from January 2013 through November 2016 at a single institute in southern Taiwan...
August 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29554828/management-of-hepatitis-b-reactivation-in-lymphoma-patients-on-rituximab-with-past-hepatitis-b-exposure-an-observational-study
#12
Denise Yeo, Ihtimam Hossain, Soon Thye Lim, Mohamad Farid, Miriam Tao, Richard Quek, Tiffany Tang, Alexandre Chan
Background Currently, a standardized approach to prevent and manage hepatitis B reactivation in lymphoma patients with past hepatitis exposure receiving rituximab in Singapore is lacking. This study is designed to report the current management approach and outcomes associated with hepatitis B reactivation. Objectives The primary objective was to report 6-, 12-, 24-month cumulative hepatitis B reactivation-related outcomes. Secondary objectives were to report monitoring frequencies of hepatitis B DNA and liver function tests performed in lymphoma patients with resolved hepatitis B receiving rituximab, and anti-viral prophylaxis use...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29551710/quantification-of-hbv-core-antibodies-may-help-predict-hbv-reactivation-in-patients-with-lymphoma-and-resolved-hbv-infection
#13
Hung-Chih Yang, Hsiao-Hui Tsou, Sung-Nan Pei, Cheng-Shyong Chang, Jia-Hong Chen, Ming Yao, Shyh-Jer Lin, Johnson Lin, Quan Yuan, Ningshao Xia, Tsang-Wu Liu, Pei-Jer Chen, Ann-Lii Cheng, Chiun Hsu
BACKGROUND & AIMS: Absence or low anti-HBV surface antibody (anti-HBs) is associated with an increased risk of HBV reactivation in patients with lymphoma and resolved HBV infection receiving rituximab-containing chemotherapy. Quantification of anti-HBV core antibody (anti-HBc) is a new marker associated with the natural history and treatment response of chronic HBV infection. This study investigated whether baseline anti-HBc and anti-HBs levels may better predict HBV reactivation...
August 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29345413/hepatitis-b-screening-before-rituximab-therapy-a-multicentre-south-australian-study-of-adherence
#14
Samuel A L Hall, Abdul Shaikh, Kailin Teh, Mahsa Tantiongco, Douglas Coghlan, Chris S Karapetis, Mohammad A Chinnaratha, Richard Woodman, Kate R Muller, Alan J Wigg
BACKGROUND: International guidelines recommend screening for hepatitis B virus (HBV) infection prior to administration of rituximab, due to high risk of HBV reactivation in at-risk patients. AIMS: To determine: (i) adherence to the South Australian (SA) protocol for HBV screening; (ii) HBV prevalence in patients receiving rituximab; and (iii) outcomes of patients at risk of HBV reactivation. METHODS: All patients commenced on rituximab at the six major SA public hospitals during a 12-month period were included in the study...
August 2018: Internal Medicine Journal
https://www.readbyqxmd.com/read/29149926/drug-induced-gastrointestinal-and-hepatic-disease-associated-with-biologics-and-nonbiologic-disease-modifying-antirheumatic-drugs
#15
REVIEW
Patrick R Wood, Liron Caplan
A variety of gastrointestinal adverse drug reactions are seen in nearly all conventional antirheumatic medications, ranging from nausea to life-threatening drug-induced liver injury. Rheumatologists should be particularly familiar with hepatotoxicity associated with long-term methotrexate use, and the range of unique hepatic, biliary, and pancreatic manifestations associated with azathioprine. Hepatitis B virus reactivation is the most serious gastrointestinal disease risk associated with many biological therapies, particularly rituximab...
February 2018: Rheumatic Diseases Clinics of North America
https://www.readbyqxmd.com/read/29066086/-hbv-infection-screening-and-treatment-for-oncology-patients
#16
REVIEW
Anaïs Jaillais, Anne Herber-Mayne, Louis D'Alteroche, Alain Landau, Yacine Merrouche, Stéphane Vignot
Patients with chronic hepatitis B infection are at risk of viral reactivation when treated by immuno- or chemotherapy, with potentially serious or even fatal consequences. This article proposes an overview on screening strategies and antiviral treatment recommendations for oncology patients. We have learned in hematology that reactivations are commun with rituximab and prophylactic treatment is recommanded for any patient who has been in contact with the virus. The risk appears to be lower with cytotoxics but has been far less studied...
February 2018: Bulletin du Cancer
https://www.readbyqxmd.com/read/28898281/randomized-prospective-study-evaluating-tenofovir-disoproxil-fumarate-prophylaxis-against-hepatitis-b-virus-reactivation-in-anti-hbc-positive-patients-with-rituximab-based-regimens-to-treat-hematologic-malignancies-the-preblin-study
#17
RANDOMIZED CONTROLLED TRIAL
María Buti, María L Manzano, Rosa M Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M Zozaya, Miguel A Simón, Luis E Morano, José L Calleja, María Yébenes, Rafael Esteban
BACKGROUND: Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal. The role of HBV prophylaxis in this setting is uncertain. The aim of this study was to compare the efficacy of tenofovir disoproxil fumarate (TDF) prophylaxis versus close monitoring in antiHBc-positive, HBsAg-negative patients under treatment with rituximab (RTX)-based regimens for hematologic malignancy. METHODS: PREBLIN is a phase IV, randomized, prospective, open-label, multicenter, parallel-group trial conducted in 17 hospitals throughout Spain...
2017: PloS One
https://www.readbyqxmd.com/read/28856548/risk-of-hepatitis-b-reactivation-in-hbsag-negative-hbcab-positive-patients-with-undetectable-serum-hbv-dna-after-treatment-with-rituximab-for-lymphoma-a-meta-analysis
#18
Zilin Tang, Xiaodong Li, Shunquan Wu, Yan Liu, Yan Qiao, Dongping Xu, Jin Li
BACKGROUND: Hepatitis B surface antigen (HBsAg)-negative/hepatitis B core antibody (HBcAb)-positive patients with undetectable serum hepatitis B virus (HBV) DNA have experienced and resolved hepatitis B virus (HBV) infection. Lymphoma patients with resolved HBV infection have high risk of HBV reactivation when treated with robust immunosuppressive agents, but the reported rate varies extensively between different studies. This study aims to estimate the risk of HBV reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab-containing chemotherapy for lymphoma...
September 2017: Hepatology International
https://www.readbyqxmd.com/read/28852481/infectious-complications-of-rituximab-therapy-in-renal-disease
#19
Andrew Nixon, Leanne Ogden, Alexander Woywodt, Ajay Dhaygude
Rituximab, an anti-CD20 monoclonal antibody, was originally used to treat B-cell malignancies. Its use has significantly increased in recent years, as it is now also used to treat a variety of autoimmune diseases including rheumatoid arthritis and ANCA-associated vasculitis (AAV). Initial studies suggested that the adverse effects of rituximab were minimal. Though the risk of malignancy with rituximab-based immunosuppressive regimens appears similar to that of the general population, there are now concerns regarding the risk of infectious complications...
August 2017: Clinical Kidney Journal
https://www.readbyqxmd.com/read/28838453/cholestasis-after-pediatric-liver-transplantation-recurrence-of-a-progressive-familial-intrahepatic-cholestasis-phenotype-as-a-rare-differential-diagnosis-a-case-report
#20
B Prusinskas, S Kathemann, D Pilic, B Hegen, P Küster, V Keitel, D Häussinger, R Büscher, H A Baba, P F Hoyer, E Lainka
INTRODUCTION: Nonobstructive cholestasis after pediatric liver transplantation is a common diagnostic and therapeutic dilemma. We describe a girl with neonatal cholestasis because of progressive familial intrahepatic cholestasis 2 (PFIC-2) and presence of a homozygous splice site mutation in the ABCB11 gene. Liver transplantation was performed because of end-stage liver disease at the age of 6. Cholestasis with normal gamma-glutamyl transferase (GGT) developed 8 years after liver transplantation...
September 2017: Transplantation Proceedings
keyword
keyword
110035
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"